Semaglutide and Handgrip Strength

A systematic review published on 19 October 2026 asked a practical question that body-composition studies often leave unresolved: what happens to measured muscle strength after adults start semaglutide? The review located 16 reports representing 11 studies. Ten studies, with 660 semaglutide-treated participants, could be pooled for handgrip strength. The pooled estimate was a change of -0.16 kgf, with a 95% confidence interval from -1.98 to 1.65 kgf, so it did not show a statistically clear average change^[1].

That is not proof that semaglutide preserves strength. The review authors rate the certainty of the evidence as very low, and their main analysis compared each treatment group with its own baseline rather than comparing semaglutide with a control group. The useful takeaway is narrower: the available studies do not yet give a reliable answer about handgrip strength.

What the review included

The authors searched MEDLINE, Embase, CENTRAL, LILACS and Google Scholar through 20 August 2026, without language restrictions. They included randomized studies, non-randomized studies and uncontrolled before-and-after studies when adults received semaglutide and researchers reported a quantitative skeletal-muscle strength outcome. Handgrip strength was reported in all 11 included studies. Only one small randomized trial assessed knee-extension strength, so that outcome was described rather than pooled^[1].

This is a strength-focused review, not a general assessment of every change that can happen during weight loss. Handgrip is a direct performance measure, while lean mass and skeletal-muscle estimates are body-composition measures. They can move differently. A lower lean-mass estimate does not, by itself, establish weaker grip, and an unchanged group-average grip result does not show that every person retained muscle tissue or physical function.

The pooled handgrip result

For the primary analysis, the team used the longest available follow-up in semaglutide-only arms and pooled within-group handgrip changes with a random-effects model. The estimate of -0.16 kgf was compatible with a small decrease, no meaningful average change, or a small increase because its confidence interval crossed zero^[1]. Duration-stratified analyses and sensitivity analyses were also nonsignificant.

The spread between individual studies was large. The statistical heterogeneity was I² = 90.8%, and the review reported a 95% prediction interval from -5.96 to 5.63 kgf^[1]. Heterogeneity means the study estimates varied more than would be expected from sampling error alone. It does not identify one reason for that variation, but it does make one average number a poor shortcut for every population, formulation or follow-up period.

Why the review cannot establish cause

Most importantly, the primary synthesis did not ask whether semaglutide produced a different strength outcome than a matched control condition. It asked how strength changed from baseline inside semaglutide groups. Without a concurrent comparator, changes in body weight, diet, exercise, illness, other care or ordinary variation can all contribute to a before-and-after result. The authors therefore conclude that the evidence does not establish strength preservation or a direct treatment effect^[1].

The review also describes the certainty as very low. That label matters. It is not a verdict that the medicine harms strength, nor a guarantee that strength is unchanged. It says further well-designed research is very likely to change confidence in the estimate. Readers should be cautious when a social post turns a null pooled result into a promise of muscle protection or a warning of inevitable weakness.

How to read this alongside body-composition research

People often encounter semaglutide research through a body-composition claim. The distinction is worth keeping. Our review of an oral semaglutide observational study describes a small cohort in which average strength was unchanged over four months while lean mass declined slightly. That study was not evidence that the drug caused either result. The new systematic review gathers a wider group of strength reports, but its authors reach a similarly careful conclusion because the comparative evidence remains limited.

A separate Japanese study measured handgrip along with diet and impedance-based body composition after oral semaglutide began. Its handgrip result did not meet the study's threshold for a change, while estimated limb muscle measures fell^[1]. Those different measures are not interchangeable. For the study details and its limits, see our 25-person oral semaglutide readout.

What stronger evidence would look like

The review calls for comparative studies with standardized strength assessment and longer follow-up. In practice, that means a study should measure strength consistently, account for participants who stop or miss follow-up, and compare outcomes against a suitable control group. It should also report the population and follow-up interval clearly enough that readers can see whether its result applies to older adults, people with diabetes, people using a medicine for obesity, or another group.

For someone taking prescribed semaglutide, this review does not supply a personalized prediction or a reason to change treatment independently. Questions about appetite, unintentional functional changes or a new difficulty with everyday tasks belong with the clinician managing the prescription. The broader evidence and approved-use context are covered in our semaglutide overview.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription medicine, and treatment decisions should be made with a qualified clinician who knows the individual's history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any product.